CLOs on the Move

Wellinks

www.wellinks.com

 
Wellinks is a virtual COPD management solution empowering members to live fully, and breathe freely.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.wellinks.com
  • 55, Whitney Avenue
    New Haven, CT USA 06510
  • Phone: 844.583.0587

Executives

Name Title Contact Details

Similar Companies

Neponset Controls Inc

Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Presbyterian Medical Services

Presbyterian Medical Services (PMS) is the successor to the United Presbyterian Churchs Medical Mission work in the Southwest which began in 1901. In 1969, an independent PMS was formed as a New Mexico non-profit corporation to ensure continuation of...

Consumer Healthcare Products Association

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to promoting the increasingly vital role of OTC medicines and dietary supplements in America`s healthcare system through science, education, and advocacy.

Vical

Vical Incorporated is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.